Harvard Apparatus withdraws IPO, plans NASDAQ listing via Harvard Bioscience spinoff

By
A A A

Harvard Apparatus Regenerative Technology, a Harvard Bioscience carve-out focusing on regenerative medicine, withdrew its plans for an initial public offering on Thursday citing poor market conditions. Instead, Harvard Bioscience plans to spin off 100% of Harvard Apparatus Regenerative Technology's common stock to its existing shareholders. The company will list on the NASDAQ under the symbol HART.

The Holliston, MA-based company, which was founded in 2009, set terms for a $19 million IPO in March. Summer Street Research Partners and Maxim Group were set to be the joint bookrunners on the deal.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: HART

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Don't Pay Up to Play REITs
Don't Pay Up to Play REITs          

Stocks

Referenced

Most Active by Volume

11,037,337
  • $97.069 ▼ 10.49%
6,450,434
  • $16.24 ▲ 14.29%
5,682,693
  • $6.7899 ▲ 0.29%
5,425,134
  • $81.37 ▲ 1.87%
5,410,950
  • $7.16 ▲ 0.70%
4,900,076
  • $17.605 ▼ 0.09%
4,335,883
  • $7.38 ▲ 0.54%
4,103,280
  • $112.31 ▲ 0.47%
As of 12/22/2014, 09:49 AM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com